EC Number |
Natural Substrates |
---|
1.1.1.184 | (4S)-3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidinone + NADPH + H+ |
99.1% conversion |
1.1.1.184 | 13,14-dihydro-15-ketoprostaglandin F2alpha + NADPH |
- |
1.1.1.184 | 4-benzoylpyridine + NADPH + H+ |
stereoselective reduction |
1.1.1.184 | 4-methylnitrosamino-1-(3-pyridyl)-1-butanone + NADPH + H+ |
i.e. NNK, genotoxic compound from tobacco smoke, isozyme 11beta-HSD1, carbonyl reductase activity, EC 1.1.1.184 |
1.1.1.184 | 4-nitrobenzaldehyde + NADPH + H+ |
- |
1.1.1.184 | 4-oxonon-2-enal + NADPH + H+ |
metabolic inactivation of the lipid peroxidation product, pathway overview |
1.1.1.184 | all-trans retinal + NADPH + H+ |
- |
1.1.1.184 | cortisol + NADPH + H+ |
- |
1.1.1.184 | daunorubicin + NADPH + H+ |
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties |
1.1.1.184 | doxorubicin + NADPH + H+ |
reduction of the anthracycline C13 carbonyl results in a 13-hydroxy metabolite that elicits potent cardiotoxic effects while possessing significantly reduced anticancer properties |